

February 11, 2026

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sirs,

Sub: Outcome of the Board meeting held on Wednesday, February 11, 2026

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Wednesday, February 11, 2026, the Board of Directors of the Company has considered and approved the unaudited financial results of the Company for the quarter ended December 31, 2025. The said unaudited financial results together with the Limited Review Report of the Statutory Auditors are enclosed herewith.

The press release with regard to the same is also enclosed herewith.

The meeting commenced at 2:30 p.m. and concluded at 5:30 p.m. (IST).

Kindly take the above on your records.

Thanking you

For AstraZeneca Pharma India Limited

Bhavana

Bhavana Agrawal
Chief Financial Officer & Director



Encl: As above

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
CIN: L24231KA1979PLC003563

Statement of unaudited financial results for the quarter and nine months ended 31 December 2025

*Rs in millions except for earnings per share data							
Sl No.	Particulars	Quarter ended 31/12/2025	Previous quarter ended 30/09/2025	Corresponding quarter ended in the previous year 31/12/2024	Nine months ended 31/12/2025	Corresponding nine months ended in the previous year 31/12/2024	Year ended 31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	a) Revenue from operations	6,115.7	5,590.9	4,402.9	16,969.7	12,358.1	17,162.9
	b) Other income	51.3	61.7	79.8	225.4	244.8	406.3
	Total income	6,167.0	5,652.6	4,482.7	17,195.1	12,602.9	17,569.2
2	Expenses						
	(a) Cost of materials consumed	-	-	698.8	94.9	1,928.8	2,871.3
	(b) Purchase of stock-in-trade	6,971.2	4,324.0	2,287.6	15,471.1	7,209.6	10,088.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,307.3)	(1,079.1)	(516.1)	(5,703.1)	(2,104.4)	(3,329.4)
	(d) Employee benefit expense	937.8	604.5	623.7	2,186.8	1,913.7	2,574.4
	(e) Depreciation and amortisation expense	38.4	25.7	90.7	229.8	223.0	399.9
	(f) Allowance for expected credit loss (net)	12.6	54.5	(1.7)	89.2	16.0	6.6
	(g) Selling, marketing and distribution expense	358.4	280.1	227.4	858.7	628.5	848.7
	(h) Other expenses	694.7	655.1	313.3	1,960.9	1,089.9	1,563.4
	(i) Finance costs	10.6	6.7	3.3	24.5	7.8	14.6
	Total expenses	5,716.4	4,871.5	3,727.0	15,212.8	10,912.9	15,037.7
3	Profit before exceptional items and tax (1-2)	450.6	781.1	755.7	1,982.3	1,690.0	2,531.5
4	Add/(Less): Exceptional items (Refer Note 5)	14.8	(52.9)	(335.5)	(41.7)	(911.1)	(967.9)
5	Profit before tax (3+4)	465.4	728.2	420.2	1,940.6	778.9	1,563.6
6	Tax expense						
	(a) Current tax	40.0	190.1	121.7	451.1	371.8	601.0
	(b) Tax expense for prior years	-	-	-	-	4.4	4.4
	(c) Deferred tax charge / (credit)	99.5	(4.1)	(10.0)	63.1	(172.2)	(199.2)
	Total tax expense	139.5	186.0	111.7	514.2	204.0	406.2
7	Profit / (loss) after tax (5-6)	325.9	542.2	308.5	1,426.4	574.9	1,157.4
8	Other comprehensive income/ (loss)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement gains / (losses) on post employment benefit obligations	0.1	(4.1)	(23.0)	4.2	(35.2)	(15.6)
	(b) Income tax effect on above	0	1.1	5.8	(1.0)	8.9	3.9
	Other comprehensive income/ (loss), net of income tax	0.1	(3.0)	(17.2)	3.2	(26.3)	(11.7)
9	Total comprehensive Income for the period (7+8)	326.0	539.2	291.3	1,429.6	548.6	1,145.7
10	Paid-up equity share capital (Face value of Rs 2/- per equity share)	50.0	50.0	50.0	50.0	50.0	50.0
11	Other Equity	-	-	-	-	-	7,653.5
12	Earnings per equity share of Rs 2/- each (basic and diluted)	13.04	21.69	12.34	57.06	22.99	46.30



Initialed For
Identification
Purpose Only

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
CIN: L24231KA1979PLC003563

Statement of unaudited financial results for the quarter and nine months ended 31 December 2025

Notes:

- 1 The Statements of unaudited financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the "Act") [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided.
- 3 During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company's manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site had ceased and the Company is in the process of sale of assets related to the manufacturing site
- 4 Pursuant to the notification by the Ministry of Labour & Employment on November 21, 2025 on the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as "the Labour Codes"), the Company has recognized provision towards past service cost on gratuity and compensated absences payable to employees amounting to Rs. 278.3 Million during the quarter ended December 31, 2025 which is included under "Employee benefit expense". The Company will continue to monitor the finalisation of Central/ State Rules and clarifications from the Government in this regard and would provide appropriate accounting effect on the basis of such developments as needed.
- 5 Exceptional Items:
 - a Exceptional items for the quarter ended 31 December 2025 and 31 December 2024 and year ended 31 March 2025 consists of expenses related to closure of the manufacturing site (Refer Note 3 above)
 - b The exceptional items during the year ended 31 March 2025 and quarter ended 31 December 2024 also consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome.
- 6 This Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 11 February 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter and nine months ended 31 December 2025.

Place: Bengaluru
Date: 11 February 2026



By Order of the Board of Directors
For AstraZeneca Pharma India Limited



Praveen Rao Akkinapally
Managing Director

Initialed For
Identification
Purpose Only

Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business park,
Rachenahalli, Outer Ring Road,
Bengaluru - 560045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended December 31, 2025 and the year to date results for the period April 1, 2025 to December 31, 2025, which are included in the accompanying "Statement of unaudited financial results for the quarter and nine months ended 31 December 2025". The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009



Sharmila Ramaswamy
Partner
Membership Number: 215131
UDIN: 26215131EEBHIX3717

Place: Bengaluru
Date: February 11, 2026

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bengaluru - 560 008
T: +91 (80) 40794188

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

AstraZeneca Pharma India Limited grew by 39% as announced during its Q3 2025-26 financial results today

Total Revenue reached INR. 6115.7 Mn in the FY- Q3 2025-26 (Oct- Dec'25)

8 new regulatory approvals for medicines or indications over the past 9 months in FY 2025-26, reinforcing leadership across therapy areas and purpose to bring innovative medicines faster in the country

Bengaluru, February 11, 2026: AstraZeneca Pharma India Limited (“the Company”), a science-led biopharmaceutical company, announced its third quarter (Oct-Dec 2025) financial results today.

The Company reported strong growth of 39% for Q3 FY'25-26, supported by consistent performance across therapy areas it is present in - Oncology, Biopharmaceuticals (CVRM, R&I, and V&I), and Rare Disease.

This consistent performance reflects **disciplined execution, strong operational efficiency, continued portfolio expansion, and increasing adoption of innovative therapies that address unmet patient needs in India.**

Financial Performance Summary:

Summary		<i>(Value in INR Mn)</i>	
		Q3 2025 Oct -Dec '25	9M 2025 Apr -Dec '25
Total revenue from Operations		6,115.7	16,969.7
Profit before exceptional item and tax		450.6	1,982.3
Profit after exceptional item and tax		465.4	1,940.6
TA wise performance	Oncology	4,395.9	12,069.5
	Biopharmaceuticals (CVRM, R&I and V&I)	1,377.4	3,834.9
	Rare Disease	65.3	107.6

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, “Our performance shows steady, portfolio-driven growth driven by disciplined execution. We are seeing consistent momentum across therapy areas as our medicines reach more patients. By continuing to strengthen our portfolio and focus on access, we aim to bring long-term value for patients and people in India.”

Praveen Akkinpally, Country President & Managing Director, AstraZeneca Pharma India Ltd., added, “The strong momentum in Q3 underscores our commitment to growth through innovation and to delivering life-changing medicines to more patients across India. It reflects confidence in AstraZeneca’s science-led strategy in the country. Guided by our purpose to push the boundaries of science, we remain focused on advancing innovation and strengthening the healthcare ecosystem to improve outcomes and reshape care nationwide, ensuring benefits reach patients across the country.”

Over the past nine months, the Company secured **8 new regulatory approvals**, further strengthening leadership across priority therapy areas and advancing its commitment to deliver science that transforms

patient outcomes. Continued strong commercial performance and unprecedented pipeline delivery in the year to date.

Key milestones:

- **Durvalumab – endometrial cancer:** Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab solution for infusion for two additional indications. Durvalumab in combination with carboplatin and paclitaxel is now indicated for first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy; followed by maintenance treatment with Durvalumab in combination with Olaparib in endometrial cancer that is *pMMR*.
- **Durvalumab – muscle invasive bladder cancer (MIBC):** Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml for an additional indication as adjuvant treatment following radical cystectomy for adult patients with MIBC.
- **Eculizumab – rare disease leadership:** Launched **Eculizumab**, the first anti-complement therapy approved in India by CDSCO for the treatment of *atypical Haemolytic Uremic Syndrome (aHUS)* and *Paroxysmal Nocturnal Hemoglobinuria (PNH)*, marking a significant milestone in rare diseases.
- **Osimertinib – NSCLC:** Received regulatory approval to import for sale and distribution of Osimertinib tablets for an additional indication in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC with *EGFR exon 19 deletions or exon 21 (L858R)* substitution mutations.
- **Trastuzumab deruxtecan – HER2 spectrum expansion:** Received regulatory approval from CDSCO to import for sale and distribution of **trastuzumab deruxtecan** for an additional indication in *HER2-low* and *HER2-ultralow* metastatic breast cancer patients who have received at least one endocrine therapy in the metastatic setting.
- **Osimertinib – NSCLC (stage III, monotherapy):** Gained CDSCO regulatory approval for an additional indication of **Osimertinib** as monotherapy for import for sale and distribution for the treatment of patients with locally advanced, unresectable (stage III) NSCLC with *EGFR exon 19 deletions or exon 21 (L858R)* substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy.
- **Benralizumab – EGPA:** Received regulatory approval from CDSCO to import for sale and distribution of **Benralizumab** for an additional indication as an add-on treatment for adult patients with relapsing or refractory *eosinophilic granulomatosis with polyangiitis (EGPA)*.
- **Sodium Zirconium Cyclosilicate (5g/10g) – Hyperkalaemia:** Received CDSCO permission for import and sale in India. The therapy is indicated for the management of hyperkalaemia in adults, particularly associated with cardiovascular, renal, and metabolic conditions (*in partnership with Sun Pharma*).

Recognitions:

- OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials.
- 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials.
- ET HRWorld EX Awards 2025: AstraZeneca Pharma India awarded for Exceptional Employee Experience (Large Scale), recognizing our progress in I&D.
- Excellence in Precision Biopharma Solutions at the VOH National Healthcare Awards 2025.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: <https://www.astrazeneca.in/> or follow us on LinkedIn: [AstraZeneca India](#).